Erlotinib: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
* Date of FDA Approval (Expiration): 2005 (2020) | * Date of FDA Approval (Expiration): 2005 (2020) | ||
* 2009 Sales: $1.2 Billion | * 2009 Sales: $1.2 Billion | ||
* Importance: It is one of the best selling and most effective treatments for several types of cancer. | * Importance: It is one of the best selling and most effective treatments for several types of cancer. It is an improved version of [[Iressa]]. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||